Amanote Research
Register
Sign In
P3.13-09 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.1849
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
B. Han
J. Lu
W. Zhang
B. Yan
L. Zhang
J. Qian
B. Zhang
S. Wang
Publisher
Elsevier BV